Welcome to our dedicated page for Repare Therapeutics Common Shares news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics Common Shares stock.
Repare Therapeutics Inc. (RPTX) is a pioneering precision medicine oncology company dedicated to the advancement of synthetic lethality-based therapies for cancer patients. The company's mission is to develop innovative oncology drugs that specifically target the vulnerabilities of tumor cells in genetically defined patient populations.
Repare utilizes an integrated approach combining insights from multiple fields of cell biology, including DNA repair and synthetic lethality. Their proprietary platform employs a high-throughput, CRISPR-enabled gene editing target discovery method alongside high-resolution protein crystallography, computational biology, and clinical informatics.
Backed by prominent global healthcare investors such as Versant Ventures and MPM Capital, Repare Therapeutics is poised at the forefront of cancer treatment innovation. The company’s robust research and development pipeline is aimed at delivering groundbreaking treatments designed to improve patient outcomes.
Repare Therapeutics has made significant strides in the oncology field, participating in numerous clinical trials and forming strategic partnerships to expedite the delivery of effective cancer therapies. With a core focus on precision oncology, the company aims to address the unmet medical needs of cancer patients worldwide. The majority of its revenue is currently derived from its operations in Canada.
For more detailed information and the latest updates, you can visit their official website at www.reparerx.com.
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations. The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with variants of unknown significance (VUS).
Key findings include:
- Recommended Phase 2 dose: 160 mg camonsertib once-daily before 4Gy radiation on days 1-5
- At 2 months: Pathogenic group showed 2 complete responses (CR), 5 partial responses (PR), 4 stable disease (SD); VUS group had 1 PR, 4 SD
- At 6 months (9 evaluable patients): Pathogenic group reported 2 CR, 4 PR, 1 SD; VUS group had 1 SD, 1 progressive disease
The results suggest potential radiosensitization and higher clinical benefit in patients with pathogenic ATM mutations compared to those with VUS.
Repare Therapeutics presented new data at AACR's Ovarian Cancer Research Symposium, highlighting the impact of FBXW7, PPP2R1A, and CCNE1 alterations in metastatic ovarian and endometrial cancers. The analysis of approximately 2,000 patients revealed:
1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a median overall survival (mOS) of 26 months compared to 36 months for those without (Lunre BM-), representing a 28% decrease in mOS.
2. Endometrial cancer: Lunre BM+ patients had an mOS of 30 months versus 41 months for Lunre BM- patients, a 27% decrease in mOS.
These findings underscore the need for innovative treatments for patients with these biomarkers. Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biomarkers, with data expected in Q4 2024.
Repare Therapeutics (Nasdaq: RPTX) will present new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial at the ESMO Congress 2024 in Barcelona. The trial evaluates camonsertib monotherapy in patients with advanced solid tumors harboring ATM loss-of-function. TRESR (NCT04497116) is a first-in-human, multi-center, open-label study designed to establish the recommended Phase 2 dose and schedule, while assessing safety, pharmacokinetics, and preliminary anti-tumor activity. Dr. Benedito A. Carneiro from Brown University will deliver an oral presentation on September 14, sharing insights on camonsertib's performance in treating these specific cancer types.
Repare Therapeutics (Nasdaq: RPTX) announced a strategic reprioritization to focus on its clinical-stage oncology programs. The company plans to reduce its workforce by 25%, primarily from the preclinical group, expecting annual savings of $15 million and extending its cash runway into H2 2026. Key highlights include:
1. Upcoming data from the MYTHIC trial (lunresertib + camonsertib) in Q4 2024
2. Potential registrational trial for lunresertib in 2025
3. Initial data from MYTHIC trial Module 4 (lunresertib + Debio 0123) in 2025
4. Initial data from TRESR trial (camonsertib monotherapy) in 2025
5. Phase 1/2 trial for RP-1664 in pediatric neuroblastoma patients
6. Phase 1 trial initiation for RP-3467 in Q4 2024
The company aims to maximize value for patients and shareholders by focusing on its most promising precision oncology programs.
Repare Therapeutics (Nasdaq: RPTX), a leading clinical-stage precision oncology company, has announced its participation in two upcoming investor conferences in September 2024. The company's senior management team will be presenting at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 1:05 p.m. ET in New York, NY, for a fireside chat.
2. H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 9:00 a.m. ET in New York, NY, for a company overview.
Live webcasts of both presentations will be available on the company's website, with replays archived for at least 30 days.
Repare Therapeutics (Nasdaq: RPTX) reported Q2 2024 financial results and provided business updates. The company reiterated its guidance on the MYTHIC trial data readout for Q4 2024. The FDA granted Fast Track designation for lunresertib in combination with camonsertib in platinum-resistant ovarian cancer. Positive initial data from Phase 1 MINOTAUR trial was presented, and the first patient was dosed in the camonsertib monotherapy NSCLC expansion of Phase 1/2 TRESR trial.
Financially, Repare reported $1.1M in Q2 revenue and $53.5M for the first half of 2024. Net R&D expenses were $30.1M, and G&A expenses were $8.3M. The net loss was $34.8M or $0.82 per share.
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients, 40% of irinotecan-naïve patients received treatment for over nine months.
The recommended Phase 2 dose (RP2D) was established at 60mg BID lunresertib continuous plus standard FOLFIRI. Importantly, the safety profile was consistent with FOLFIRI alone, with the most common serious adverse events being neutropenia and leukopenia.
These findings, presented at the ESMO GI Cancers Congress, suggest lunresertib combined with FOLFIRI could offer a new treatment option for patients with CCNE1 amplification and FBXW7 mutations, which lack approved therapies.
Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in the expansion of its TRESR clinical trial, focusing on camonsertib monotherapy for non-small cell lung cancer (NSCLC) with ATM mutations. This expansion follows the rapid return of global rights to Repare. The TRESR trial aims to address the unmet need of over 5,000 patients with recurrent NSCLC in the US, UK, and top EU markets. Current treatments offer progression-free survival of around four months. The trial will enroll up to 20 patients to evaluate the efficacy of camonsertib at the recommended Phase 2 dose, with data expected in 2025.
Repare Therapeutics (Nasdaq: RPTX) has received Fast Track designation from the FDA for its combination therapy of lunresertib and camonsertib for treating platinum-resistant ovarian cancer in patients with specific genetic profiles (CCNE1 amplification, FBXW7, or PPP2R1A mutations). This treatment is currently in Phase 1 dose expansion trials. The FDA previously granted Fast Track designation for the same combination in treating endometrial cancer. Repare plans to present data from these trials in the fourth quarter of 2024, involving 20-30 patients each for ovarian and endometrial cancers. The Fast Track designation aims to expedite the development and review processes to bring significant new therapies to patients sooner.
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that its senior management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will take place on June 10, 2024, at 2:40 p.m. Eastern Time in Miami, FL. The session will include a fireside chat, and a live webcast will be available on Repare's investor relations website.
The webcast replay will be accessible for 90 days post-event.
FAQ
What is the current stock price of Repare Therapeutics Common Shares (RPTX)?
What is the market cap of Repare Therapeutics Common Shares (RPTX)?
What does Repare Therapeutics Inc. specialize in?
What unique technology does Repare Therapeutics use?
Who are the major investors backing Repare Therapeutics?
Where does Repare Therapeutics derive its maximum revenue from?
What is the focus area of Repare Therapeutics' research and development?
Where can I find more information about Repare Therapeutics?
How does Repare Therapeutics identify drug targets?
What fields of cell biology does Repare Therapeutics integrate insights from?
What is the significance of synthetic lethality in Repare Therapeutics' approach?
Is Repare Therapeutics involved in clinical trials?
